Description
HER2/neu is a protein receptor that becomes overexpressed in approximately 2-5% of colorectal cancers, making it a potential therapeutic target. Anti-HER2 targeted therapies are used to treat colorectal tumors that demonstrate HER2 amplification or overexpression when other treatment options have been exhausted.
Mechanism of Action
HER2-targeted agents bind to the HER2 protein receptor on cancer cell surfaces, blocking growth signals that promote tumor proliferation and survival. This targeted approach leads to cancer cell death and tumor shrinkage in HER2-positive colorectal cancers.
Side Effects
Diarrhea
Fatigue
Nausea
Decreased appetite
Abdominal pain
Vomiting
Constipation
Peripheral neuropathy
Cardiac toxicity
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT00091286
Early Phase 1
Archived
Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer
United States